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Abstract
Introduction: Systemic delivery of bone marrow-derived mesenchymal stem cells (MSC) seems to be of benefit in
the treatment of multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS) sustained by
migration of T cells across the brain blood barrier (BBB) and subsequent induction of inflammatory lesions into CNS.
MSC have been found to modulate several effector functions of T cells. In this study, we investigated the effects of
MSC on adhesion molecules and receptors on T cell surface that sustain their transendothelial migration.
Methods: We used different co-culture methods combined with real-time PCR and flow cytometry to evaluate the
expression both at the mRNA and at the plasma-membrane level of α4 integrin, β2 integrin, ICAM-1 and CXCR3. In
parallel, we assessed if MSC are able to modulate expression of adhesion molecules on the endothelial cells that
interact with T cells during their transendothelial migration.
Results: Our in vitro analyses revealed that MSC: (i) inhibit proliferation and activation of both peripheral blood
mononuclear cells (PBMC) and CD3+-selected lymphocytes through the release of soluble factors; (ii) exert suppressive
effects on those surface molecules highly expressed by activated lymphocytes and involved in transendothelial migration;
(iii) inhibit CXCL10-driven chemotaxis of CD3+ cells; (iv) down-regulated expression of adhesion molecules on
endothelial cells.
Conclusions: Taken together, these data demonstrate that the immunosuppressive effect of MSC does not exclusively
depends on their anti-proliferative activity on T cells, but also on the impairment of leukocyte migratory potential
through the inhibition of the adhesion molecules and receptors that are responsible for T cell trafficking across
BBB. This could suggest a new mechanism through which MSC modulate T cell responses.
Keywords: mesenchymal stem cells, CD3+-selected lymphocytes, human endothelial cells, immunosuppressive
effects, surface adhesion molecules and receptors, transendothelial migration, leukocyte migratory potential
Introduction
The central nervous system (CNS) is an immune-privileged
site where the endothelial blood–brain barrier (BBB) tightly
controls lymphocyte entry. Under physiological conditions,
lymphocyte traffic across the BBB is low, but during inflam-
matory diseases of the CNS—such as multiple sclerosis
(MS) or its animal model, experimental autoimmune
encephalomyelitis (EAE)—circulating CD4+ and CD8+ lym-
phocytes gain access to the CNS leading to inflammation,
demyelination, and neurodegeneration [1–3]. Preventing
the migration of lymphocytes into the CNS seems to be an
important therapeutic approach for MS, and adhesion
molecules on lymphocytes have long been studied as pos-
sible targets [4, 5] possibly leading to the translation into
relevant therapies for MS [6].
Integrins are one of the major families of adhesion
molecules that mediate binding of leukocytes to vascular
endothelium leading to their extravasation [7], and they
are probably involved in demyelinating diseases [8–10].
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Integrins typically consist of α and β subunits [7]; α4
integrin interacts with β1 integrin forming the very late
antigen-4 (VLA-4) antigen expressed on T and B cells.
VLA-4 is responsible for lymphocyte binding to endo-
thelial cells [8, 9]; the ability of T cells to induce EAE
seems to correlate with α4 integrin expression [10, 11].
In addition, the monoclonal antibody (mAb) natalizu-
mab (NTZ), developed to treat relapsing–remitting MS,
selectively binds α4 integrin on autoreactive T cells and
thus reduces their extravasation into CNS [12]. Also β2
integrin acts in leukocyte trafficking as a constituent of
the lymphocyte function-associated antigen-1 (LFA-1)
that binds the intercellular adhesion molecules (ICAMs)
on endothelial cells [3]. Other molecules seem to be in-
volved in the pathogenesis of MS. In particular, ICAM-1,
a member of the Immunoglobulin Superfamily (IgSF)
that is weakly expressed on resting lymphocytes but
highly expressed on endothelial cells [13, 14], is induced
by inflammatory mediators [14–16] and acts in transmi-
gration of T cells, of T-helper type (Th) 17 lymphocytes
in particular [17]. Also the chemokine receptor CXCR3
on the lymphocyte surface seems to act in the patrolling
of the CNS [18] and may play a role in MS pathogenesis
[19] because it triggers rapid leukocyte adhesion and is
induced in activated CD4+ and CD8+ T cells crossing the
BBB [18–20].
The molecular counterparts for lymphocyte trafficking
into the CNS are the adhesion molecules on endothelial
cells of the BBB, whose expression typically increases
under inflammatory conditions [21]. Among these, the
most important are ICAM-1 and the activated leucocyte
cell adhesion molecule (ALCAM) that are upregulated
by inflammatory stimuli [22, 23]. In particular, postmor-
tem sections from patients with MS and mice with EAE
showed higher expression of ALCAM. Moreover, mAbs
against ALCAM reduced the accumulation of CD4+ T
cells, decreased the disease severity, and delayed the
onset of EAE [22, 23]. For this reason, ALCAM has been
recently associated with risk, development, and progres-
sion of MS [24].
Mesenchymal stem cells (MSC) are progenitor cells of
mesodermal origin that can be found in almost every
connective tissue, including the bone marrow where they
have been well characterized [25]. MSC are capable of
modulating immune responses [26, 27] by having an
anti-apoptotic effect on different cell types including T
lymphocytes [28] and neurons [29, 30], as well as by releas-
ing trophic factors and favoring endogenous neurogenesis
[29–31]. MSC have therefore emerged as a promising tool
for therapeutic applications in neurological experimental
conditions, such as for the treatment of EAE, through
inducing T-cell tolerance against myelin antigens, reducing
T-cell infiltrates in the CNS [32], inhibiting the encephali-
togenic potential of autoreactive T cells and axonal loss
[33], and protecting from oxidative stress damage [31, 34].
Since the 1990s, MSC have been used in clinical settings in
humans to promote the engraftment of hematopoietic
stem cells (HSC) [35, 36] and to treat immune-mediated
diseases such as acute graft versus host disease (GvHD)
[37]. Some studies demonstrated that MSC inhibit cell
proliferation and decrease interferon gamma (IFNγ) pro-
duction in T cells, probably through the secretion of sol-
uble factors but also by “cell to cell contact” mechanisms
[28, 38, 39]. In addition, soluble proinflammatory factors
released by activated lymphocytes strongly influence MSC
modulatory activity, supporting the idea of an intense
cross-talk between MSC and immune cells [40, 41]. Des-
pite the large amount of studies, little is known on the abil-
ity of MSC to affect the expression of molecules sustaining
the lymphocyte–BBB interaction necessary for the lympho-
cytes to gain access to inflamed tissues.
Here we hypothesized that MSC may modulate the
capability of activated lymphocytes to cross the BBB and
reach the CNS, at least in part, by selectively acting on
specific adhesion molecules and chemokine receptors in-
volved in the extravasation of activated T cells. In the
light of their possible implication in pathogenesis of MS,
we explored the ability of human MSC to modulate the
expression, both at the mRNA level and at the plasma-
membrane level, of α4 integrin, β2 integrin, CXCR3, and
ICAM-1 on CD3+ lymphocytes, and of ICAM-1 and
ALCAM on endothelial cells.
Methods
Chemicals
All chemicals, unless otherwise indicated, were of analyt-
ical grade and were obtained from Sigma-Aldrich Corp.
(Milan, Italy).
Human mesenchymal stem cell isolation and cell culture
Human bone marrow samples were obtained from healthy
donors undergoing bone marrow explant from allogeneic
transplantation procedures. Informed consent, approved
by the local Ethics Committee (Regione Liguria), was
obtained from all donors. Donors’ age ranged between 22
and 54 years (mean = 38.6). Mononuclear cells were
isolated by density gradient centrifugation (1.077 g/ml,
Lympholyte Cell separation Media; Cedarlane Laboratories
Ltd, Burlington, Ontario, Canada), and cultured in Human
Mesencult Basal Medium additioned with its specific sup-
plement (Stem Cell Technologies, Vancouver, BC, Canada)
at 37 °C in a humidified 5 % CO2 atmosphere. MSC grow-
ing as adherent cells were harvested at 80 % of confluence
using Trypsin 0.05 %–ethylenediamine tetraacetic acid
(EDTA) 0.02 % and then expanded. MSC were character-
ized by flow cytometry at each passage and used upon
phenotypic characterization as CD73+, CD44+, CD105+,
CD90+, CD45−, CD34−, and CD14− cells [28]. For each
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experiment we used the BM-derived MSC from a single
donor, and the experiment was repeated using MSC from
different donors.
Peripheral blood mononuclear cell isolation, CD3+
lymphocyte selection, and coculture with MSC
Peripheral blood mononuclear cells (PBMC) were sepa-
rated by density gradient centrifugation from heparin-
ized blood of healthy donors after informed consent
[28]. PBMC were resuspended in RPMI 1640 supple-
mented with L-glutamine, penicillin, streptomycin and
10 % fetal calf serum (FCS) and dispensed in microtiter
200 μl plates (Sarstedt S.r.l, Verona, Italy) at a concen-
tration of 1 × 105 cells/well. Upon stimulation with 2 μg/
ml anti-Human OKT3 (R&D Systems, Milan, Italy) and
1 μg/ml anti-Human CD28 (BD Biosciences, San Jose,
CA, USA) antibodies, PBMC were cultured alone or in
the presence of MSC from different donors at three
different PBMC/MSC ratios (20:1, 10:1, and 4:1). After 4
days, cells were harvested and used for experiments.
CD3+ lymphocytes were isolated from the PBMC by
magnetic negative selection using a Pan T isolation kit
(Miltenyi Biotech GmBh, Bergish Gladbach, Germany).
Briefly, PBMC were resuspendend in RPMI without FCS,
plated at a concentration of 2 × 106 cells/ml, and main-
tained for 5 minutes at 37 °C to allow the adhesion of
monocytes. The monocyte-depleted cells were then har-
vested, resuspended in phosphate-buffered saline (PBS)–
0.02 % EDTA at a concentration of 107 cells/40 μl, and
incubated with 10 μl Biotin Antibody Cocktail for 10 mi-
nutes at 4 °C. After incubation with anti-Biotin microbeads
for 15 minutes, cells were washed, resuspended in PBS–
0.02 % EDTA (107 cells/500 μl), and applied on MS
columns (Miltenyi Biotech GmBh) following the manufac-
turers’ instructions. CD3+ cells were then employed in
transwell experiments using flat-bottom microtiter plates
(Millipore, Milan, Italy). CD3+ cells were dispensed at a
concentration of 1 × 105cells/well in the lower chamber
previously coated with αCD3 (10 μg/ml) and αCD28 (1 μg/
ml) mAbs. MSC were seeded in the upper chamber and
three different CD3+/MSC ratios were used (20:1, 10:1, and
4:1). After 4 days, cells were harvested and used for
experiments.
For all treatments we checked the viability of cells by
Trypan Blue staining, which resulted to be over 95 %
also at the highest coculture ration with MSC ratio (4:1).
Human endothelial cell culture and expansion
Human endothelial cells (HECV; Cell Bank and Culture in
GMP-IST, Genoa, Italy) were maintained at 37 °C in a hu-
midified 5 % CO2 atmosphere in Dulbecco’s modified
Eagle’s medium high glucose (DMEM) supplemented with
L-glutamine, penicillin, streptomycin and 10 % FCS. HECV
were characterized by flow cytometry as CD166+, CD105+,
CD54+, CD146+ MHC class I, CD102−, and CD106− cells.
In coculture experiments, HECV were dispensed at a con-
centration of 1 × 106 cells/well using flat-bottom 24-well
plates and stimulated with recombinant human IFNγ (200
IU/ml; Invitrogen Co., Carlsbad, California, USA). Cells
were then incubated with MSC from different donors in
transwell conditions (TW) at three different HECV/MSC
ratios (20:1, 10:1, and 4:1) for 24 hours. MSC were seeded
in the upper chamber and HECV in the lower chamber.
Before seeding HECV were irradiated at 5000 rad, washed
once with PBS, counted, and plated with or without MSC.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from either lymphocytes or
endothelial cells using the Trizol reagent (Sigma Aldrich,
Saint Louis, Missouri, USA) [42]. First-strand cDNA was
synthesized in a Master-cycler apparatus (Eppendorf,
Milan, Italy) from 1 μg total RNA as described elsewhere
[43]. Gene expression levels were quantified by quantita-
tive real-time RT-PCR (qPCR) using Chromo4TMSystem
PCR apparatus and iTaq SYBR Green Supermix (Biorad,
Milan, Italy). Amplification reactions were performed in a
final volume of 25 μl containing 0.3 μM each primer,
10 ng cDNA, 1× SybrGreen PCR Master Mix. All
primers (Table 1) were designed ad hoc starting from
the coding sequences available on the GenBank data-
base (http://www.ncbi.nlm.nih.gov/Genbank/Genbank
Search.html) and were synthesized by TibMolBiol custom
oligosynthesis service. A melting curve of RT-PCR products
(55–94 °C) was acquired to ensure the absence of artifacts.
Relative expression of target mRNA was calculated using
the comparative Cq method and was normalized for the
expression of GAPDH gene [44]. The normalized expres-
sion was thus expressed as the relative quantity of mRNA
(fold induction) with respect to controls (C).
Flow cytometric analysis of lymphocyte surface antigens
Cells were stained with the specific primary mAb for 30
minutes at 4 °C, washed once with PBS, and analyzed. For
coculture experiments, cells were additionally stained with
Live Dead Fixable Near–IR Dead Cell-Stain Kit (Invitro-
gen) for 30 minutes at room temperature to exclude apop-
totic cells by flow cytometric gating strategies (FSC-A vs.
FL6-A dotplot). All immunolabeling procedures, unless
otherwise indicated, were performed in the dark. The
following mAbs were employed: CD34FITC, CD73PE,
CD44FITC, CD14FITC, CD45FITC, CD45PE-Cy5, CD54
APC, CD54PE-Cy5 (BD Biosciences), CXCR3FITC and
CXCR3APC (R&D Systems), CD49d PE, CD90PE-Cy5,
CD105APC, CD102PE, and CD106 APC (Biolegend Europe
BV, London, UK), and KI67FITC (Dako Italia SpA, Milan,
Italy). On the CD3+ lymphocyte population, the proportion
of cells expressing α4 integrin, ICAM-1, and CXCR3 in the
different experimental conditions was measured. On HECV,
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we recorded the shift in the mean fluorescence intensity
(MFI) for each adhesion molecule under the different ex-
perimental conditions. Moreover, production of IFNγ by ac-
tivated CD3+ lymphocytes was determined using Flow
Cytomix particle-based assay (Biosciences, Prodotti Gianni,
Milan, Italy), according to the manufacterer’s instructions
[45]. All flow cytometric analyses were performed by a
FACS Canto flow cytometer (BD Biosciences) and data were
collected and analyzed by DIVA software (BD Biosciences).
Flow Cytomix particle-based assay data were analyzed with
FlowCytomixPro 1.0 Software, eBioscience, San Diego, Cali-
fornia, USA.
CD3+ cell proliferation analysis
Cell proliferation was measured by 3H-thymidine (3H-TdR)
incorporation. CD3+ cells cultured in the absence or in the
presence of MSC in a transwell system were pulsed with
0.5 μCi/well 3H-TdR (5 Ci/mmole specific activity; GE
Healthcare Europe GmbH, Milan, Italy) for 8 hours. At the
end of incubation, cells were harvested onto Multiscreen
Harvest plates (Millipore, Billerica, MA, USA) using a 96-
well plate-automated cell harvester (Tomtec, Handem, CT,
USA). Scintillation liquid (Fisher Chemicals, Leicester, UK)
was then added and 3H-TdR incorporation was measured
by liquid scintillation spectroscopy using a beta-counter
(Chameleon TM 425-104 Multilabel Counter -Bioscan,
Washington, USA). The results expressed in counts per mi-
nute (kcpm, cpm× 1000) are given as the mean value of
triplicate wells. In the same experiments, CD3+ cells cocul-
tured as already described were also analyzed by flow cy-
tometry for Ki67 intranuclear expression to identify KI67+
cycling T cells.
CD3+ lymphocyte migration analysis
Chemotaxis of CD3+ lymphocytes was investigated using
24-transwell plates with 5 μm pore size polycarbonate
membrane (Corning Costar, Celbio, Milan, Italy) as re-
ported elsewhere [46]. CD3+ lymphocytes were grown
for 48 hours with or without MSC (4:1 ratio) in the pres-
ence of αCD3 (10 μg/ml) and αCD28 (1 μg/ml) in a
transwell system. Then, 5 × 105 CD3+ lymphocytes were
dispensed in the upper chamber, whereas 600 ng/ml
CXCL10 (IP10; R&D Systems) or medium alone was
added to the lower chamber. Plates were incubated for 2
hours at 37 °C, and then cells that migrated into the
lower chamber were harvested and counted. Results
were expressed as % input, calculated as the % ratio
between the number of CD3+ cells dispensed in the
upper chamber and that of cells recovered from the
lower chamber after migration. Net % input (namely the
difference between the input obtained following chemo-
kine stimulation and that obtained with medium alone)
was used for statistical analysis of the results.
Statistical analysis
Data of qPCR are expressed as mean ± standard deviation
(SD) of two independent RNA extractions from at least
five independent experiments, and each PCR was per-
formed in quadruplicate. Data of flow cytometry are
expressed as mean ± SD of the frequency of populations
measured in at least five independent experiments. Statis-
tical significance was determined by analysis of variance
followed by the Bonferroni post-hoc test (Instat software;
GraphPad Software, Inc., San Diego, CA, USA). The
Mann–Whitney U test was used for chemotaxis-related
experiments.
Results
MSC inhibit T-cell proliferation and function
In preliminary experiments, activated PBMC were cocul-
tured with MSC at different PBMC/MSC ratios (20:1,
10:1, and 4:1) using both the cell-to-cell contact (CC)
and TW in order to select the experimental model to be
used in the study. When IFNγ expression was assessed
by qPCR, a significant upregulation was observed in ac-
tivated PBMC with respect to controls (19-fold; p <0.001)
(Fig. 1a). In the CC condition (Fig. 1a), MSC led to a
dose-dependent reduction in IFNγ expression with a de-
crease of −94 % with respect to activated cells (p <0.001)
in the presence of the highest MSC dose (PBMC/MSC
Table 1 Sequences of the primer pairs used for quantitative real-time RT-PCR analysis
Gene Accession
number
Forward primer Reverse primer
5'→ 3' 5'→ 3'
α4 integrin NM_000885.4 GGAATATC AGTTTTTACACAAAGG AGA GAG CCA GTC CAG TAA GAT GA
β2 integrin NM_001114380.1 GCTGTCCCCACAAAAAGTG CCG GAA GGT CAC GTT GAA
CXCR3 NM_001142797.1 CCAGCCATGGTCCTTGAG GGG CCG TAC TTC CTC AAC T
ICAM-1 NM_000201.2 CAACCGGAAGGTGTATGAAC CGA GGT GTT CTC AAA CAG CTC
IFNγ NM_000619.2 GGCATTTTGAAGAATTGGAAAG TTT GGA TGC TCT GGT CAT CTT
ALCAM NM_001627.2 CGT CTG CTC TTC TGC CTC TT TAG GTG CCT CAA ACA CGT TG
GAPDH NM_002046.3 AACCACTCCTCCACCTTTGACGC CTC TTG TGC TCT TGC TGG GGC TG
ALCAM activated leucocyte cell adhesion molecule, IFNγ interferon gamma, ICAM intercellular adhesion molecule
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ratio 4:1), and of about −80 % (p <0.001) for the other
ratios. Similar effects were observed in TW (Fig. 1a),
where the maximum reduction in IFNγ mRNA level
(−92 % with respect to activated cells; p <0.001) was
observed at the 4:1 PBMC/MSC ratio, but a signifi-
cant decrease of about −83 % (p <0.01) was observed
also at 20:1 and 10:1 ratios. As these data clearly in-
dicate that MSC effects on PBMC do not depend on
CC, we used TW to test the possible effects of MSC
on PBMC proliferation by using 3H-TdR incorpor-
ation (Fig. 1b). PBMC consistently proliferated upon
in vitro activation (mean 0.11 ± 0.03 vs. 29.02 ± 1.31,
unstimulated vs. stimulated, respectively; p <0.001). A
dose-dependent inhibition of cell proliferation was
observed when cells were cocultured with MSC at all
PBMC/MSC ratios for 4 days (means 3.05 ± 1.07,
1.68 ± 0.14, and 0.67 ± 0.18 for 20:1, 10:1, and 4:1 ratios,
respectively; p <0.001). Correspondingly, most PBMC
cultured in the absence of MSC constitutively expressed
Ki67, a classical marker of cell proliferation, and its
expression strongly decreased in the presence of MSC in a
dose-dependent manner (data not shown).
Using TW, expression and secretion of IFNγ was mea-
sured in selected CD3+ lymphocytes cocultured with MSC
in TW (Fig. 1c). After activation, CD3+ cells showed a
marked upregulation of IFNγ expression (about sevenfold
with respect to control; p <0.001) that was significantly re-
duced in the presence of MSC. The maximum reduction
(−67 % with respect to activated cells; p <0.001) was ob-
served at the highest MSC dose (CD3/MSC ratio 4:1), but
a significant decrease of about −33 % (p <0.01) was
observed also at 20:1 and 10:1 ratios (Fig. 1c). On the
same samples, the secretion of IFNγ in the medium was
evaluated using flow cytometry (Fig. 1d). The IFNγ level
increased in activated CD3+ cells (141-fold with respect
to resting cells; p <0.001) and decreased in a dose-
dependent manner when CD3+ cells were cocultured
with MSC at all CD3/MSC ratios (p <0.01) (Fig. 1c).
Finally, the ability of CD3+ cells to form cluster was
assessed by light optical microscopy (Fig. 1e, upper and
lower). According to expectations, CD3+ cell clusters were
observed upon stimulation with αCD3/αCD28 (Fig. 1e,
upper), while the presence of MSC in coculture with
CD3+ cells prevented cluster formation (Fig. 1e, lower).
Fig. 1 Effects of MSC on T-cell proliferation and function. In PBMC in resting conditions (N.A.) or after activation via αCD3/αCD28 mAb, we assessed
the mRNA expression of IFNγ by qPCR a and cell proliferation by 3H-TdR incorporation b in the absence or in the presence of MSC for all PBMC/MSC
ratios (20:1, 10:1, and 4:1), either in CC (squared bars) or in TW (solid colored bars) condition. In activated CD3+ lymphocytes we assessed both the mRNA
expression c and secretion d of IFNγ in the absence or in the presence of MSC at all CD3/MSC ratios (20:1, 10:1, and 4:1) in TW. Cluster formation of
CD3+ lymphocytes was assessed by light microscopy e. Images were acquired after 2-day stimulation of CD3+ lymphocytes with plate-bound αCD3/
αCD28 in the absence or in the presence of MSC (CD3/MSC 4:1 ratio) in TW (20× magnification). Clusters are marked with arrows. PCR data (mean ± SD)
are reported as fold induction with respect to controls after normalization for GAPDH mRNA. Significant differences are denoted by symbols on bars:
activated vs. N.A. cells, *p ≤0.01, **p ≤0.001, ***p ≤0.0001; MSC-treated vs. MSC-untreated cells, $p ≤0.01, $$p ≤0.001, $$$p ≤0.0001. IFNγ interferon, MSC
mesenchymal stem cells, PBMC peripheral blood mononuclear cells
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MSC inhibit expression of adhesion molecules on CD3+
lymphocytes
At first, the basal expression of the adhesion molecules
under analysis was assessed in resting CD3+ lympho-
cytes. While α4 integrin mRNA was expressed in basal
conditions, both ICAM-1 and β2 integrin were barely
detectable (Cq values of about 25 for α4 integrin, and 32
for ICAM-1 and β2 integrin) (data not shown).
At mRNA level, α4 integrin expression was upregulated
upon activation with respect to resting CD3+ lymphocytes
(2.7-fold induction; p <0.001) (Fig. 2a). A significant
reduction with respect to activated cells (−57 %; p <0.001)
was observed with the highest MSC dose in TW (4:1
CD3/MSC ratio); an evident but not significant effect
could be appreciated also at 20:1 and 10:1 ratios. Activated
CD3+ cells showed also a significant increase in mRNA
expression of ICAM-1 with respect to resting lympho-
cytes (7.1-fold induction; p <0.001) (Fig. 2b). Also in
this case the highest MSC dose significantly reduced
ICAM-1 expression with respect to activated CD3+
cells (−86 %; p <0.001) (Fig. 2b). For comparison,
similar experiments were performed on PBMC cocul-
tured with MSC at different PBMC/MSC ratios (20:1,
10:1, and 4:1) using both CC and TW, and similar in-
hibitory effects were observed in both culture condi-
tions (data not shown).
Although activated CD3+ cells did not show any signifi-
cant increment in mRNA level of β2 integrin with respect
to resting cells, a significant reduction of about −67 %
(p <0.001) was observed for all the CD3/MSC ratios
without a dose dependence (Table 2).
Flow cytometry studies performed in parallel showed
that α4 integrin was constitutively expressed at the plasma
membrane level on resting CD3+ lymphocytes (mean
52.25 ± 13.87) (Fig. 2c), while very low expression (mean
2.76 ± 1.98) was observed for ICAM-1 (Fig. 2d), in accord-
ance with qPCR data. Upon in vitro activation, CD3+ cells
showed a slight increase in the proportion of α4 integrin
(mean 66.81 ± 19.7, p <0.01), and a marked increase in
the proportion of ICAM-1 (mean 94.5 ± 3.47, p <0.001)
with respect to resting cells. The presence of MSC in
TW slightly reduced the proportion of α4 integrin on
Fig. 2 Effects of MSC on the expression of CD3+ lymphocyte adhesion molecules. In activated CD3+ lymphocytes cultured in the absence or in
the presence of MSC in TW, the relative mRNA expression of α4 integrin a and of ICAM-1 b was evaluated by qPCR. Data (mean ± SD) are reported as
fold induction with respect to controls after normalization for GAPDH mRNA. The proportion of cells which express α4 integrin c and of ICAM-1 d on the
T-cell membrane was evaluated by flow cytometry in the same experimental conditions. Results are expressed as mean percentage ± SD obtained from
six independent experiments. Activated vs. N.A. cells, *p ≤0.01, **p ≤0.001, ***p ≤0.0001; MSC-treated vs. MSC-untreated cells, $p ≤ 0.01,
$$p ≤0.001, $$$p ≤0.0001. ICAM intercellular adhesion molecule, MSC mesenchymal stem cells, N.A. PBMC in resting conditions
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the CD3+ surface with respect to activated cells (−7 %
for 20:1 ratio, −13 % for 10:1 ratio, and −22 % for 4:1
ratio), but the statistical significance was reached only
with the highest dose of MSC (p <0.001) (Fig. 2c). The
presence of MSC markedly reduced also the proportion
of ICAM-1 on the cell membrane in a dose-dependent
manner (−9.7 % for 10:1 ratio and −15.4 % for 4:1 ratio;
p <0.05 and p <0.001, respectively) (Fig. 2d). No differences
were observed for β2 integrin upon exposure to MSC at
different ratios (data not shown).
Inhibition of CXCR3 expression by MSC reduced CXCL10-
dependent chemotaxis of T cells
We observed that CXCR3 was constitutively expressed in
resting CD3+ cells, and its transcription increased signifi-
cantly (Fig. 3a) upon activation with αCD3/αCD28 (5.6-
fold induction with respect to resting cells; p <0.001). This
change was still detectable at plasma membrane level
(Fig. 3b), although the increase in the CXCR3 proportion
on the cell membrane did not reach significance (means
37.1 + 8.58 vs. 45.13 ± 10.21). The upregulation of CXCR3
expression was prevented by the presence of MSC in a
dose-dependent manner. Both the 10:1 and 4:1 CD3/MSC
ratios were effective on preventing the upregulation of
CXCR3, which showed a significant reduction of −50 %
and −80 %, respectively, with respect to activated cells
(p <0.001) (Fig. 3a). These effects were evident also at
plasma membrane level, where the presence of MSC
led to a dose-dependent reduction in the proportion of
CXCR3 on the plasma membrane (−28.1 % for 20:1
Table 2 Relative expression of β2 integrin mRNA in activated
CD3+ lymphocytes cultured in the absence or in the presence
of MSC at three CD3/MSC ratios (20:1, 10:1, and 4:1)
Treatments Fold induction
Activated CD3+ cells 0.87 ± 0.28
Activated CD3+ cells + MSC 20:1 0.29 ± 0.33**
Activated CD3+ cells + MSC 10:1 0.30 ± 0.35**
Activated CD3+ cells + MSC 4:1 0.28 ± 0.18***
mRNA expression was evaluated by qPCR, and values representing the mean
± SD of three different experiments are reported as fold induction with respect
to controls (no activated CD3+ lymphocytes) after normalization for GAPDH
mRNA. Significant differences: MSC-treated cells vs. activated cells, **p ≤0.01,
***p ≤0.001
MSC mesenchymal stem cells
Fig. 3 Effects of MSC on CXCR3 expression and function. a Activated CD3+ lymphocytes were cultured in the absence or in the presence of MSC
in TW, and the mRNA expression of CXCR3 was evaluated by qPCR. Data (mean ± SD) are reported as fold induction with respect to controls after
normalization for GAPDH mRNA. b In the same experimental conditions, the proportion of CXCR3 on T-cell membrane was evaluated by flow
cytometry. Results are expressed as mean percentage ± SD obtained from six independent experiments. c Fluorescence histograms of CXCR3-
labeled CD3+ cells cultured in TW for 48 hours with or without MSC (4:1 ratio) in the presence of plate–bound αCD3/αCD28. Results are expressed as
median percent of positive cells. d Chemotaxis of activated CD3+ cells cultured with MSC at 4:1 ratio in response to either CXCL10 or medium alone.
Activated vs. N.A. cells, *p ≤0.01, **p ≤0.001, ***p ≤0.0001; MSC-treated vs. MSC-untreated cells, $p ≤0.01, $$p ≤0.001, $$$p ≤0.0001. MSC mesenchymal
stem cells, N.A. PBMC in resting conditions
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ratio, −28.4 % for 10:1 ratio, and −31.5 % for 4:1 ratio;
p <0.001) (Fig. 3b).
In order to explore whether the effects of MSC reflect
on the CXCR3-related T-cell function, the chemotactic
activity of activated CD3+ cells was assessed. CD3+ cells
were cultured for 2 days in the absence or in the pres-
ence of MSC in TW (CD3/MSC 4:1 ratio). Then, the
expression of CXCR3 and the response to CXCL10, the
selective ligand of CXCR3, were evaluated. We found a
marked decrease in CXCR3 expression on the surface of
CD3+ cell cultured with MSC with respect to activated
cells (means 48.36 ± 10.03 vs. 22.44 ± 11.84; p <0.01) that
was paralleled by a significant (p <0.05) inhibition of
CXCL-10-driven chemotaxis (Fig. 3c, d).
MSC inhibit expression of adhesion molecules on HECV
The possible effects of MSC on endothelial cells were
assessed focusing on some adhesion molecules relevant
for their interaction with T cells. HECV constitutively
express ALCAM and ICAM-1 at both mRNA and mem-
brane level (MFI = 1927 ± 488.88 and MFI = 7311 + 1398,
respectively) (Fig. 4), whereas no constitutive expression
of either V-CAM-1 or ICAM-2 was observed both at the
mRNA and the membrane level (data not shown).
Upon stimulation with IFNγ, HECV showed a marked
increase in ICAM-1 expression at both the mRNA (10.1-
fold induction with respect to controls; p <0.001) and the
plasma membrane (mean 14,599 ± 1635.42, p <0.001)
levels (Fig. 4a, b, respectively). Also ALCAM expression
was upregulated by IFNγ at the mRNA level (1.8-fold
induction; p <0.01), but the increase was not significant at
the membrane level (mean = 2406 ± 520.99) (Fig. 4c, d,
respectively). The upregulation of ICAM-1 mRNA expres-
sion was reduced by the presence of MSC at all HECV/
MSC ratios (−33 %, −59 %, and −68 % for 201:1, 10:1,
and 4.1 ratios, respectively, with respect to activated
cells; p <0.001) (Fig. 4a). Also, at the plasma membrane
level, MSC reduced ICAM-1 with respect to stimulated
cells (MFI = 14,599 for stimulated HECV vs. MFI = −2517,
MFI = −2624, and MFI = − 2288 for 20:1, 10:1, and 4:1
HECV/MSC ratios, respectively; p <0.01) (Fig. 4b). The
upregulation of ALCAM expression was prevented by
the presence of MSC at all HECV/MSC ratios both at
the mRNA (about −55 % for all ratios with respect to
stimulated cells) (Fig. 4c) and at the plasma membrane
level (MFI = 2406 for stimulated HECV vs. MFI = −711,
MFI = −726, and MFI = −504 for 20:1, 10:1, and 4.1
HECV/MSC ratios, respectively; p <0.01); a slight decrease
was observed at the highest HECV/MSC 4:1 ratio; p <0.05
(Fig. 4d).
Discussion
In this study, we demonstrated that MSC significantly act
on adhesion molecules and receptors localized on both T-
lymphocyte and endothelial cell membrane whose interac-
tions are involved in lymphocyte extravasation and traf-
ficking across the BBB. T-cell homing into the CNS is very
low in physiological conditions, but it remarkably in-
creases under inflammatory cues such those occurring in
EAE and MS when encephalitogenic CD4+ and CD8+ cells
infiltrate the CNS [1]. The process of leukocyte extravasa-
tion consists of a finely regulated sequence of steps that is
mediated by different classes of surface molecules sustain-
ing the interaction between leukocytes and endothelial
cells [3, 47]. The initial contact of activated lympho-
cytes with the BBB endothelium is mediated by selec-
tins [3], while integrins trigger the subsequent firm
adhesion [11, 12], and then the interaction between
ICAM-1 on T cells and ALCAM on endothelial cells
led to the final diapedesis [21, 22].
With regards to therapy of MS and other autoimmune
diseases, the ultimate goals are twofold: to eliminate/
reduce the self-reactive lymphocytes halting the immune
attack to the CNS; and to attempt repair of the existing
damage. Many studies indicated that transplantation of
MSC is of functional benefit in animal models of MS
[33, 34]. Different mechanisms have been suggested in-
cluding induction of immune tolerance toward myelin
antigens, release of trophic and anti-apoptotic factors,
and induction of endogenous neurogenesis [48]. Inter-
estingly, MSC decrease T-cell infiltration in the CNS of
mice with EAE [33] and impair the encephalitogenic
potential of T cells [34]. Based on the results presented
in this manuscript, we provide a significant insight into
the possible molecular mechanism impairing T-cell ex-
travasation under inflammatory conditions as mimicked
by the exposure of both T cells and endothelial cells to
IFNγ. Although these in vitro results should be cau-
tiously considered as validation of the in vivo mecha-
nisms of action of administered MSC and by no means
as an indication of optimal yields of cells to be trans-
planted, they are a solid “proof of concept” permitting to
elucidate the possible interactions between MSC, im-
mune cells, and endothelial cells, which might be rele-
vant for some clinical conditions such as MS.
At first, we observed that, in vitro, MSC inhibit IFNγ
expression by PBMC upon αCD3/αCD28 stimulation
using both CC and TW. This clearly indicates that
such an effect does not depend on a physical contact
between MSC and PBMC, but on soluble factors re-
leased by MSC. Moreover, MSC play a profound and
dose-dependent inhibition of PBMC proliferation and,
interestingly, MSC presence blocks PBMC in G0/G1
phases of the cell cycle as shown by the decrease in ex-
pression of KI67 (data not shown), in accordance with
previous reports [28, 49]. On the other hand, MSC
exerted the same inibitory effects on selected CD3+
lymphocytes.
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In the light of their effects on activation of CD3+ lym-
phocytes, we investigated whether MSC act on the pool
of molecules involved in T-cell trafficking into the CNS
such as α4 integrin, β2 integrin, ICAM-1, and CXCR3.
We found a decrease in the level of α4 integrin upon
MSC exposure. In particular, we observed that activated
T cells overexpressed α4 integrin and this upregulation
was prevented by the presence of MSC in TW. This
effect of MSC on activated T cells in vitro resembles the
effects played by the mAb NTZ in vivo [50]. NTZ is
“the first of a new class of drugs known as elective adhe-
sion molecule inhibitor” employed to treat relapsing-
remitting MS [5], and Harrer et al. [50] described a
reduction in both α4 and β1 levels on T-cell, B-cell, and
natural killer cell membrane in response to NTZ therapy
in MS patients. Our results suggest that MSC may
mimic the effect of NTZ on α4 integrin expression in T
cells, and this could represent one of the molecular
mechanisms supporting the clinical efficacy of MSC
transplantation in the animal model of MS. By contrast,
β2 integrin, the constituent of LFA-1 antigen required
for a broad range of leukocyte actions, was not upregu-
lated in stimulated CD3+ cells, in accordance with previ-
ous data showing that activation of T cells via the T-cell
receptor (TCR) did not change LFA-1 expression [51].
However, MSC are able to reduce the mRNA level of β2
integrin and this action could be synergic with the in-
hibitory effect on α4 integrin possibly leading to a
strengthening of the inhibition of T-cell extravasation.
Activation of CD3+ cells also led to an increased ex-
pression of CXCR3, a key receptor of Th1 lymphocytes,
and this upregulation was inhibited by the presence of
MSC in a dose-dependent manner. It has to be noted
that T lymphocytes isolated from the cerebrospinal fluid
(CSF) of MS patients express high levels of CXCR3 [19]
and that CXCR3+ T cells are present in the infiltrates ob-
served in MS tissues [19]. Here, we demonstrated that
not only expression of CXCR3 on CD3+ lymphocytes,
but also their ability to migrate under the chemotactic
stimulus of CXCL10, which has a relevant role in the
pathophysiology of MS [52], is inhibited by MSC. This
result is of particular interest because it indicates that
Fig. 4 Effects of MSC on expression of HECV adhesion molecules. HECV stimulated using IFNγ were cultured for 24 hours in the absence or in the
presence of MSC at the HECV/MSC ratios of 20:1, 10:1, and 4:1 in TW. The relative mRNA expression of ICAM-1 a and ALCAM c were evaluated by
qPCR. Data (mean ± SD) are reported as fold induction with respect to controls. In the same experimental conditions, the mean fluorescence
intensity (MFI) of plasma membrane expression of ICAM-1 b and ALCAM d was evaluated by flow cytometry following staining with specific mAb.
Results of six independent experiments are expressed as mean percentage ± SD of recorded MFI. Activated vs. N.A. cells, *p ≤0.01, **p ≤0.001,
***p ≤0.0001; MSC-treated vs. MSC-untreated cells, $p ≤0.01, $$p ≤0.001, $$$p ≤0.0001. ALCAM activated leucocyte cell adhesion molecule,
HECV human endothelial cells, ICAM intercellular adhesion molecule, MSC mesenchymal stem cells, N.A. PBMC in resting conditions
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MSC also inhibit the effector function of T cells, in con-
trast to a previous study showing that the inhibitory ef-
fect of MSC was confined to proliferation of T cells
rather than to their effector functions [53]. Taken to-
gether, our data suggest that the inhibition exerted by
MSC on CXCR3 expression might cooperate with the
other changes induced on het CD3+ cell surface to pre-
vent intrathecal accumulation of T cells in MS.
In line with our finding, an earlier report stated that
blocking CXCR3 function was associated with less severe
EAE and diminished T-cell infiltration of the CNS [54],
although other studies reported that CXCR3−/− mice de-
velop more severe EAE [55] and that CXCR3 signaling
has a protective role by retaining the T cells in the peri-
vascular compartment [56].
Similar suppressive action of MSC was observed on
ICAM-1 expression. ICAM-1 is constitutively expressed
at low levels on T cells and is strongly upregulated fol-
lowing stimulation. By contrast, ICAM-1 expression is
high in the endothelial cells and is further increased
upon stimulation with IFNγ. Here, we demonstrated that
MSC modulate ICAM-1 expression on both T cells and
endothelial cells by decreasing the frequency of CD3+ cells
expressing ICAM-1, and the antigen density on HECV.
Such an effect is relevant since it indicates a stronger
immunomodulation effect of MSC through a bidirectional
action that, on one side, blocks ICAM-1 expression on the
T-lymphocyte surface and, on the other side, decreases
ICAM-1 expression in the endothelial cell membrane. This
effect may be considered protective, despite previous
controversial results. In fact, some reports showed that
blocking of ICAM-1 led to a protective outcome in EAE
[4, 57], whereas other studies reported no protection or
even increased disease severity [58, 59]. On the other hand,
an attenuated disease was observed in ICAM-1 null
mutant mice (ICAM-1null), which are deficient in all
ICAM-1 isoforms [60]. However, we must not forget that
blocking of ICAM-1 in vivo affects both leukocyte and
endothelial cells, and previous studies showed that the role
of ICAM-1 in EAE development was linked to its expres-
sion on both endothelial cells and T lymphocytes [61, 62].
When we investigated the possible cross-talk between
MSC and endothelial cells, we observed that MSC in cocul-
ture with HECV decreased IFNγ-dependent upregulation
of ALCAM, an adhesion molecule expressed on endothelial
cells [63]. Interestingly, in both MS and EAE, ALCAM
expression at the BBB level is upregulated in active lesions
[23]. Our finding therefore suggests that suppressive action
of MSC on T-cell infiltration is strengthened by their effect
on adhesion molecules localized on endothelial cells.
Taken together, our results indicate that MSC act
directly on both T lymphocytes and endothelial cells by
reducing the expression of those surface molecules highly
expressed upon inflammatory stimuli playing a role in the
T-cell–endothelial cell interaction at the BBB, thus
possibly affecting the consequent lymphocyte entry into
CNS. Although these results have been exclusively obtained
in vitro, the ability of MSC to decrease the expression of
key molecules involved in the migration of T cells into the
CNS reinforces their therapeutic efficacy in treating MS
[48]. Moreover, changes induced on the lymphocyte surface
are strengthened by the inhibition of T-cell proliferation
and of the chemokine-driven chemotaxis. All of these
events may act in synergy and could explain the observa-
tion of a reduced number of T cells infiltrating the CNS
upon MSC administration [33]. By using different coculture
systems we have also clarified that the action of MSC
mainly occurs through the release of soluble factors and
does not require physical contact between lymphocytes
and endothelial cells. Interestingly, these soluble factors are
not constitutively secreted by MSC but only under the
condition of cross-talk with activated lymphocytes. In fact,
when lymphocytes were incubated in MSC-conditioned
medium—that is, medium containing soluble factors
secreted by MSC in basal conditions without coculture
with PBMC—no effects were observed at the level of the
surface molecules under analysis (data not shown).
In conclusion, although MSC are described as cells hav-
ing high differentiation potential, their effector functions
seem to be based less on in situ transdifferentiation or
fusion ability, and more on paracrine effects and cross-
talk with other cells present within diseased tissues. In
particular, MSC might exert their therapeutic effects also
through the inhibition of extravasation of T cells, an event
of high relevance for the treatment of MS.
Conclusions
The results of this study will enhance our knowledge
about the mechanisms sustaining the immunosuppressive
action of MSC by focusing on the interaction between
MSC and endothelial cells. Our findings indicate that the
immunosuppressive effect of MSC does not exclusively
depend on their anti-proliferative activity on T cells, but
also on the impairment of leukocyte migration through
the BBB by acting on those adhesion molecules and recep-
tors that are responsible for T-cell rolling.
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